MannKind Corp
MNKD
About: MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
Employees: 407
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
482% more call options, than puts
Call options by funds: $6.48M | Put options by funds: $1.11M
7% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 70
3.07% less ownership
Funds ownership: 58.06% [Q1] → 54.99% (-3.07%) [Q2]
11% less funds holding
Funds holding: 254 [Q1] → 227 (-27) [Q2]
27% less capital invested
Capital invested by funds: $887M [Q1] → $647M (-$240M) [Q2]
54% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 48
67% less funds holding in top 10
Funds holding in top 10: 3 [Q1] → 1 (-2) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
|
Oppenheimer
Andreas Argyrides
|
$15
|
Outperform
Maintained
|
5 Sep 2025 |
|
Wells Fargo
Tiago Fauth
|
$10
|
Overweight
Maintained
|
3 Sep 2025 |
|
HC Wainwright & Co.
Brandon Folkes
|
$11
|
Buy
Maintained
|
2 Sep 2025 |
|
RBC Capital
Douglas Miehm
|
$8
|
Outperform
Maintained
|
26 Aug 2025 |
Financial journalist opinion
Based on 11 articles about MNKD published over the past 30 days
